Novo Nordisk | NVO - Debt


Novo Nordisk reported DKK118.72B in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
ANI Pharmaceuticals USD 620.31M 1.25M Sep/2025
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Bausch Health Companies USD 21.04B 696M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Drreddys Laboratories INR 67.73B 19.09B Dec/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 32.64B 1.37B Jun/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pacira USD 376.72M 203.77M Sep/2025
Perrigo USD 3.64B 7.2M Sep/2025
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.04B 1.7M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Supernus Pharmaceuticals USD 42.21M 10.44M Sep/2025
Zoetis USD 7.27B 482M Sep/2025